Trump announces all 50 states will join Medicaid drug-pricing model
Published · Updated
What happened
President Donald Trump announced that every state would join a Medicaid drug-pricing model that would benchmark selected medicines to "Most Favored Nation" prices. The statement described nationwide participation and implied a change in how some Medicaid drug payments would be set.
Why it matters
A nationwide Medicaid pricing model can change expected federal and state outlays for prescription drugs, while also affecting pharmaceutical revenue, rebate structures, and the timing of budget savings. The next steps matter because administrative guidance, state confirmations, and court filings will determine whether the announced model becomes operative on the timetable implied by the White House.
President Donald Trump said on September 18 that all 50 states would participate in a Medicaid drug-pricing model using "Most Favored Nation" pricing for selected medicines. The announcement, if implemented through federal and state administrative action, would alter reimbursement assumptions for Medicaid drug spending and open a near-term window for litigation, industry pushback, and implementation disputes. The development matters immediately for budget officials because claimed savings may enter fiscal messaging before legal and operational details are settled.
Watch for
Centers for Medicare & Medicaid Services publication of formal Medicaid guidance or a state plan amendment template by 2026-09-22 HHS or CMS release naming the covered drugs and benchmark pricing methodology by 2026-09-22 PhRMA or a named manufacturer filing for injunctive relief in federal court against the Medicaid pricing model by 2026-09-22 National Association of Medicaid Directors acknowledgement of state implementation steps or objections by 2026-09-22
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made